Pancreatic Cancer Dietary Assessment Study

You may be eligible if

• Patients with histologically/cytologically-proven or clinically-suspected (by specialist MDT) pancreatic malignancy including pancreatic ductal adenocarcinoma or pancreatic NET.
• Patients to be seen in the Medical Oncology HPB and NET team clinic for assessment
• Age ≥18 years with no upper age limit
• Patients must be able to give informed consent; Written consent will be required for patients to be included within the diagnostic cohort Verbal consent only will be required for patients to be included within the demographic cohort and the follow-up cohort
• Additional cohort-specific criteria;
• Patients will be recruited into three different cohorts with differing levels of participation (termed demographic, diagnostic and follow-up). Patients will not be recruited into the follow-up cohort until recruitment of both demographic and diagnosis cohorts are complete and the interim analysis has been performed.
• Demographic cohort \| All patients referred for consideration of cancer treatment options will be eligible. Patients will need to give verbal informed consent.
• Diagnosis cohort \| Patients who are already consented for being included into the demographic cohort and who will be attending at least to one follow-up appointment and are considered to be fit enough for diagnostic assessment will be eligible. Patients will need to give written informed consent.
• Follow-up cohort \| All patients referred for consideration of options of cancer treatment will be included; patients with a minimum of 3 months of follow-up will be included in the final analysis. Patients will need to give verbal informed consent.